Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Biotechnology
The Food and Drug Administration yesterday granted approval for UK pharm major AstraZeneca’s (LSE: AZN) Truqap (capivasertib) with Faslodex (fulvestrant). 17 November 2023
Biotechnology
US drug developer SpringWorks Therapeutics today announced what it described as positive top-line results from its Phase IIb ReNeu trial evaluating mirdametinib. 16 November 2023
Biotechnology
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). 16 November 2023
Pharmaceutical
Japanese pharma major Astellas Pharma has entered into a merger agreement to acquire Propella Therapeutics. 16 November 2023
Biotechnology
Adding to the collaboration agreed last December, Gilead Sciences’ subsidiary Kite has today announced it is expanding it collaboration with US biotech Arcellx. 15 November 2023
Biotechnology
Antibody specialist Nona Biosciences has entered into a strategic collaboration with Chinese bioconjugation company GeneQuantum Healthcare. 15 November 2023
Pharmaceutical
Markets have reacted warmly to a radical plan from Theseus Pharmaceuticals to cut costs and potentially put itself up for a sale or merger. 15 November 2023
Pharmaceutical
German life sciences and pharma company Merck KGaA, which operates its Healthcare business as EMD Serono in the USA and Canada, yesterday announced that it plans to move its US Healthcare headquarters, currently located in Rockland, Massachusetts, to Boston’s Seaport district. 15 November 2023
Biotechnology
London-listed blood disease specialist Hemogenyx Pharmaceuticals has announced the successful completion of the re-manufacturing of an improved lentivirus (LVV) devoid of splice variants. 15 November 2023
Biotechnology
UK pharma major AstraZeneca today announced two developments for its best-selling cancer drug Imfinzi (durvalumab). 14 November 2023
Biotechnology
Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO). 13 November 2023
Biotechnology
Legend Biotech Corporation has entered into an exclusive, global license agreement with Swiss pharma giant Novartis. 13 November 2023
Biotechnology
Tarlatamab demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial. 13 November 2023
Biotechnology
Canadian biotech Zymeworks has reacquired rights for the antibody-drug conjugate (ADC) zanidatamab zovodotin, from partner BeiGene. 13 November 2023
Biotechnology
Following US approval in the same indication earlier this year, Japanese drugmaker Daiichi Sankyo’s Vanflyta (quizartinib) has now also been approved in the European Union (EU). 13 November 2023
Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines and two biosimilars for approval at its November 2023 meeting. 11 November 2023
Biotechnology
Jazz Pharmaceuticals has agreed terms with the MD Anderson Cancer Center for a five-year strategic research collaboration. 10 November 2023
Pharmaceutical
Germany’s Bayer and Recursion Pharmaceuticals, a US techbio firm seeking to decode biology to industrialize drug discovery, have updated the focus of their research collaboration to precision oncology. 10 November 2023
Biotechnology
UK oncology-focussed biotech ValiRx edged up 2.5% to 12.30 pence this morning, after it announced it has entered into an agreement with StingRay Bio to investigate a lead series of drug candidates for use in oncology. 10 November 2023
Biotechnology
WuXi XDC has published a prospectus for its upcoming initial public offering (IPO), detailing plans to raise $470 million with a listing on the Hong Kong Stock Exchange. 9 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze